These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29773595)

  • 1. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
    He J; Chen Q; Gu H; Chen J; Zhang E; Guo X; Huang X; Yan H; He D; Yang Y; Zhao Y; Wang G; He H; Yi Q; Cai Z
    Haematologica; 2018 Aug; 103(8):1369-1379. PubMed ID: 29773595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib.
    Xu L; Feng J; Tang H; Dong Y; Shu M; Chen X
    Cell Death Dis; 2020 Apr; 11(4):297. PubMed ID: 32341332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
    Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
    Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
    Liu Z; Jing Q; Wang Y; Li Y; Mi F; Xiang C; Fu R
    Int J Mol Med; 2019 Jan; 43(1):285-293. PubMed ID: 30387821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
    Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
    Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
    Gao S; Li X; Zang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
    Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
    Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response].
    Xu L; Tang HL; Gong X; Xin XL; Dong Y; Gao GX; Shu MM; Chen XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):450-4. PubMed ID: 25948203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
    Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy.
    Cao HY; Li L; Xue SL; Dai HP
    Hematol Oncol; 2023 Aug; 41(3):301-309. PubMed ID: 36251458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
    Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
    Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
    Wu YF; Ou CC; Chien PJ; Chang HY; Ko JL; Wang BY
    Phytomedicine; 2019 Mar; 56():94-102. PubMed ID: 30668358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
    Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
    Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.
    Cao L; Chen Q; Gu H; Li Y; Cao W; Liu Y; Qu J; Hou Y; Chen J; Zhang E; He J; Cai Z
    Clin Epigenetics; 2022 Jul; 14(1):84. PubMed ID: 35799216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
    Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
    Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
    Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
    Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.